DK1861403T3 - Hidtil ukendte imidazol[1,5-a]pyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater der indeholder dem - Google Patents

Hidtil ukendte imidazol[1,5-a]pyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater der indeholder dem

Info

Publication number: DK1861403T3
Authority: DK; Denmark
Prior art keywords: pharmaceutical compositions; compositions containing; processes; preparation; pyridine derivatives
Prior art date: 2005-03-16

Application number

DK06726093.5T

Other languages

English (en)

Inventor

Marie-Francoise Bordes

Francoise Bono

Alain Badorc

Chantal Alcouffe

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-16

Filing date

2006-03-15

Publication date

2012-08-13

2006-03-15 Application filed by Sanofi Sa filed Critical Sanofi Sa

2012-08-13 Application granted granted Critical

2012-08-13 Publication of DK1861403T3 publication Critical patent/DK1861403T3/da

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 3
LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical class C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)

DK06726093.5T 2005-03-16 2006-03-15 Hidtil ukendte imidazol[1,5-a]pyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater der indeholder dem DK1861403T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0502590A FR2883286B1 (fr)	2005-03-16	2005-03-16	NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
PCT/FR2006/000567 WO2006097625A1 (fr)	2005-03-16	2006-03-15	NOUVEAUX DÉRIVÉS D'IMIDAZO[1,5-a]PYRIDINES, LEUR PROCÉDÉ DE PRÉPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT.

Publications (1)

Publication Number	Publication Date
DK1861403T3 true DK1861403T3 (da)	2012-08-13

Family

ID=35276198

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06726093.5T DK1861403T3 (da)	2005-03-16	2006-03-15	Hidtil ukendte imidazol[1,5-a]pyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater der indeholder dem

Country Status (24)

Country	Link
US (2)	US8008321B2 (da)
EP (1)	EP1861403B1 (da)
JP (1)	JP5007295B2 (da)
KR (1)	KR101278374B1 (da)
CN (2)	CN101160309A (da)
AT (1)	ATE556074T1 (da)
AU (1)	AU2006224466B2 (da)
BR (1)	BRPI0607589A2 (da)
CA (1)	CA2599643C (da)
CY (1)	CY1112997T1 (da)
DK (1)	DK1861403T3 (da)
EA (1)	EA013408B1 (da)
ES (1)	ES2386643T3 (da)
FR (1)	FR2883286B1 (da)
IL (1)	IL185611A (da)
MA (1)	MA29716B1 (da)
MX (1)	MX2007011361A (da)
NO (1)	NO20075169L (da)
NZ (1)	NZ561205A (da)
PL (1)	PL1861403T3 (da)
PT (1)	PT1861403E (da)
SI (1)	SI1861403T1 (da)
WO (1)	WO2006097625A1 (da)
ZA (1)	ZA200707901B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200804284A (en) *	2006-03-31	2008-01-16	Speedel Experimenta Ag	Process for preparing 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one
WO2008110523A1 (en)	2007-03-09	2008-09-18	Probiodrug Ag	Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
CN103204852A (zh)	2007-04-10	2013-07-17	H.隆德贝克有限公司	作为p2x7拮抗剂的杂芳基酰胺类似物
CN102056907B (zh) *	2008-04-04	2014-12-31	武田药品工业株式会社	杂环衍生物及其用途
WO2010108503A1 (en)	2009-03-24	2010-09-30	Life & Brain Gmbh	Promotion of neuronal integration in neural stem cell grafts
FR2962437B1 (fr) *	2010-07-06	2012-08-17	Sanofi Aventis	Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr)	2010-07-06	2012-08-17	Sanofi Aventis	Derives d'indolizines, procedes de preparation et application en therapeutique
FR2967412B1 (fr) *	2010-11-17	2012-12-14	Sanofi Aventis	Nouveaux derives d'indolizine, leur preparation et leur application en therapeutique
EP2727410A4 (en)	2011-07-01	2015-03-25	Nokia Corp	METHOD AND DEVICE FOR PROVIDING NETWORK ACCESS TO A CONNECTING DEVICE
FR2985185B1 (fr)	2012-01-04	2013-12-27	Sanofi Sa	Utilisation en therapeutique de derives d'imidazopyridine
WO2014005150A1 (en) *	2012-06-29	2014-01-03	Novartis Ag	Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
AR094812A1 (es)	2013-02-20	2015-08-26	Eisai R&D Man Co Ltd	Derivado de piridina monocíclico como inhibidor del fgfr
US20150216860A1 (en) *	2013-03-10	2015-08-06	National University Corporation Nagoya University	Therapeutic agent for systemic bone disease and use thereof
US9868722B2 (en)	2013-12-10	2018-01-16	Cleave Biosciences, Inc.	Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex
CN103910643B (zh) *	2014-04-23	2015-07-15	温州大学	一种抗癌活性甲酮衍生物、合成方法及其用途
FR3022244B1 (fr) *	2014-06-17	2016-07-01	Centre Nat De La Rech Scient (Cnrs)	Utilisation d'un nouveau compose 3-aryl-4-catechol-pyrrole-n-propanol et ses derives pour le traitement du cancer et des pathologies associees a une angiogenese excessive
WO2016027781A1 (ja)	2014-08-18	2016-02-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	単環ピリジン誘導体の塩およびその結晶
CN114984013A (zh)	2015-03-25	2022-09-02	国立癌症研究中心	胆管癌治疗剂
CR20180109A (es) *	2015-07-20	2018-05-03	Genzyme Corp	Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r)
AU2016374441B2 (en)	2015-12-17	2021-10-21	Eisai R&D Management Co., Ltd.	Therapeutic agent for breast cancer
BR112020017922A2 (pt)	2018-03-28	2020-12-22	Eisai R&D Management Co., Ltd.	Agente terapêutico para carcinoma hepatocelular
CN110483437B (zh) *	2018-05-14	2022-12-06	嘉兴维眸生物科技有限公司	一种含五元环的化合物及其制备和应用
CN110183442A (zh) *	2019-06-06	2019-08-30	无锡合全药业有限公司	一种1 -(乙氧羰基)咪唑并[1, 5]吡啶-6-羧酸的合成方法
US11530216B2 (en)	2020-12-23	2022-12-20	Genzyme Corporation	Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors
CN113735849B (zh) *	2021-07-22	2022-10-11	安徽中医药大学	1-氰基咪唑并[1,5-a]吡啶类化合物及其合成方法
CN113603687A (zh) *	2021-08-02	2021-11-05	北京工业大学	一种氰基取代的咪唑[1,5-a]并吡啶合成新方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5738647A (en) *	1996-09-27	1998-04-14	Becton Dickinson And Company	User activated iontophoretic device and method for activating same
FR2838123B1 (fr) *	2002-04-04	2005-06-10	Sanofi Synthelabo	Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
FR2896247B1 (fr) *	2006-01-13	2008-02-29	Sanofi Aventis Sa	Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique

2005
- 2005-03-16 FR FR0502590A patent/FR2883286B1/fr not_active Expired - Fee Related
2006
- 2006-03-15 CN CNA2006800126910A patent/CN101160309A/zh active Pending
- 2006-03-15 EA EA200701991A patent/EA013408B1/ru not_active IP Right Cessation
- 2006-03-15 PT PT06726093T patent/PT1861403E/pt unknown
- 2006-03-15 SI SI200631369T patent/SI1861403T1/sl unknown
- 2006-03-15 AT AT06726093T patent/ATE556074T1/de active
- 2006-03-15 AU AU2006224466A patent/AU2006224466B2/en not_active Ceased
- 2006-03-15 WO PCT/FR2006/000567 patent/WO2006097625A1/fr not_active Ceased
- 2006-03-15 CA CA2599643A patent/CA2599643C/fr not_active Expired - Fee Related
- 2006-03-15 EP EP06726093A patent/EP1861403B1/fr not_active Expired - Lifetime
- 2006-03-15 NZ NZ561205A patent/NZ561205A/en not_active IP Right Cessation
- 2006-03-15 ES ES06726093T patent/ES2386643T3/es not_active Expired - Lifetime
- 2006-03-15 ZA ZA200707901A patent/ZA200707901B/xx unknown
- 2006-03-15 CN CN2010105440758A patent/CN102050821A/zh active Pending
- 2006-03-15 BR BRPI0607589-4A patent/BRPI0607589A2/pt not_active IP Right Cessation
- 2006-03-15 KR KR1020077021179A patent/KR101278374B1/ko not_active Expired - Fee Related
- 2006-03-15 PL PL06726093T patent/PL1861403T3/pl unknown
- 2006-03-15 JP JP2008501368A patent/JP5007295B2/ja not_active Expired - Lifetime
- 2006-03-15 DK DK06726093.5T patent/DK1861403T3/da active
- 2006-03-15 MX MX2007011361A patent/MX2007011361A/es active IP Right Grant
2007
- 2007-08-30 IL IL185611A patent/IL185611A/en not_active IP Right Cessation
- 2007-09-14 US US11/855,549 patent/US8008321B2/en active Active
- 2007-09-26 MA MA30249A patent/MA29716B1/fr unknown
- 2007-10-10 NO NO20075169A patent/NO20075169L/no not_active Application Discontinuation
2011
- 2011-02-04 US US13/020,883 patent/US8633216B2/en active Active
2012
- 2012-08-02 CY CY20121100690T patent/CY1112997T1/el unknown

Also Published As

Publication number	Publication date
ZA200707901B (en)	2009-01-28
US20080108648A1 (en)	2008-05-08
KR20070113227A (ko)	2007-11-28
FR2883286A1 (fr)	2006-09-22
EP1861403A1 (fr)	2007-12-05
SI1861403T1 (sl)	2012-08-31
MX2007011361A (es)	2007-11-12
BRPI0607589A2 (pt)	2009-09-15
IL185611A0 (en)	2008-01-06
US20110136856A1 (en)	2011-06-09
JP5007295B2 (ja)	2012-08-22
CA2599643C (fr)	2014-02-11
AU2006224466A1 (en)	2006-09-21
US8008321B2 (en)	2011-08-30
ES2386643T3 (es)	2012-08-24
CY1112997T1 (el)	2016-04-13
US8633216B2 (en)	2014-01-21
EA200701991A1 (ru)	2008-02-28
NO20075169L (no)	2007-12-12
CA2599643A1 (fr)	2006-09-21
PL1861403T3 (pl)	2012-10-31
JP2008533111A (ja)	2008-08-21
EA013408B1 (ru)	2010-04-30
AU2006224466B2 (en)	2012-02-16
MA29716B1 (fr)	2008-09-01
KR101278374B1 (ko)	2013-06-25
PT1861403E (pt)	2012-07-20
NZ561205A (en)	2009-09-25
CN101160309A (zh)	2008-04-09
ATE556074T1 (de)	2012-05-15
FR2883286B1 (fr)	2008-10-03
EP1861403B1 (fr)	2012-05-02
IL185611A (en)	2013-11-28
CN102050821A (zh)	2011-05-11
WO2006097625A1 (fr)	2006-09-21

Publication	Publication Date	Title
IL185611A0 (en)	2008-01-06	Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
WO2007090141A3 (en)	2007-11-15	Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
MXPA05012025A (es)	2006-02-03	Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
NO20050525L (no)	2005-05-06	Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
WO2004074244A3 (en)	2004-11-11	Pyrimidine compounds
SE0202539D0 (sv)	2002-08-27	Compounds
NO20070339L (no)	2007-03-19	1-aza-bicyklo[3 3.1]nonaner
NO20090295L (no)	2009-01-20	Substituerte heteroarylderivater
MXPA05012026A (es)	2006-02-03	Compuestos de azaindol como inhibidores de cinasa.
MY148634A (en)	2013-05-15	Pyridazinone derivatives
DE60204452D1 (de)	2005-07-07	Pyrazolo[1,5]pyridinderivate
NO20074666L (no)	2007-11-09	Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer
MX2009008540A (es)	2009-08-18	Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
NO20066055L (no)	2007-01-24	Pyridinderivater
NO20090346L (no)	2009-02-19	Pyrazolderivater som inhibitorer av cytokrom P450
NO20074258L (no)	2007-11-27	Pyridin-2-karboksamidderivater som MGLUR5 antagonister
TW200613243A (en)	2006-05-01	Novel compounds
SE0400284D0 (sv)	2004-02-10	Novel compounds
SE0401762D0 (sv)	2004-07-05	Novel compounds
NO20063062L (no)	2006-08-30	Imidazolderivater, fremgangsmate for fremstilling og anvendelse av disse
TNSN07440A1 (en)	2009-03-17	Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
NZ552137A (en)	2009-08-28	New 4-benzylidene-piperidin derivatives
UA90285C2 (ru)	2010-04-26	Производные гидантоина, полезные как ингибиторы металлопротеиназ
NO20064344L (no)	2006-10-19	Caspaseinhibitorer og anvendelser derav
UA89801C2 (en)	2010-03-10	Novel hydantoin derivatives as metalloproteinase inhibitors